Navigation Links
Phyhealth Signs Agreement with Advantica EyeCare to Provide Vision Services for Pilot HMO
Date:4/24/2008

MIAMI, April 24 /PRNewswire-FirstCall/ -- Physicians Healthcare Management Group, Inc. (Phyhealth) (Pink Sheets: PHYH), a developer of health maintenance organizations (HMOs) in partnership with physicians, today announced that Phyhealth Plan Corporation, a wholly-owned subsidiary of Phyhealth, has signed an agreement with Advantica EyeCare to provide comprehensive vision services for its Pilot HMO scheduled to be launched in the latter half of 2008.

Mr. Robert Trinka, chairman and chief executive officer, stated, "We are pleased to have Advantica EyeCare on board as a premium provider of vision services for our Pilot HMO members. With its wide selection of comprehensive vision plans and pre-paid vision care benefits, plan participants can make choices that are best suited to their needs. Advantica's creative benefit options were an important consideration in our due diligence process as was its reputation for quality care."

Mr. Richard Sanchez, chief executive officer and president of Advantica EyeCare, commented, "Phyhealth's novel approach to healthcare is commendable and we look forward to participating in the company's Pilot HMO that will be launched right here in our home state of Florida. We believe that Phyhealth is on the right path to improving the effectiveness and costs associated with healthcare through the establishment of its community-based HMOs that are consumer-driven and where physicians, the HMO and the patients' interests are aligned. At Advantica, we focus on consumer driven management of eye health and vision care and we fully appreciate Phyhealth's commitment to keeping patients healthy."

About Physicians Healthcare Management Group, Inc.

Physicians Healthcare Management Group, Inc. (Phyhealth) is a developer of community-based health maintenance organizations (HMOs) that are owned and operated in partnership with the participating physicians. Phyhealth Plans are designed to deliver high-quality affordable h
'/>"/>

SOURCE Physicians Healthcare Management Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Phyhealth Files Historical Financials With the Pink Sheets and Takes Next Step Toward Becoming Fully Reporting
2. Phyhealth HMO Applications Accepted by All Required Federal and State Agencies
3. Phyhealth Submits HMO Applications with Required Federal and State Agencies
4. Phyhealth Concludes $1.5 Million Financing for Launch of Its Pilot Community-Based HMO
5. Xceed Molecular Signs University of Florida to Strategic Collaborator Program; Focus on Developing New Molecular Test to Diagnose Early-Stage Bladder Cancer
6. Breckenridge Pharmaceutical Signs Letter of Intent for Long Term Agreement With Orit Laboratories (West Caldwell, NJ)
7. New Patient Monitoring Devices Handle More Than Just Vital Signs
8. Medical Futures signs North American licensing rights to New Biologic agent for Ulcerative Colitis
9. Governor Rendell Signs Bill Into Law
10. Medical Marketing Veteran Signs on as Director of Strategy and New Business Development at Active Imagination
11. Pharsight Signs New Diabetes Meta-Database Customer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... News) -- One in five American men admits ... a new survey shows. A nationally representative ... such violence is more prevalent than diabetes. This ... slapping and hitting, kicking, biting, choking, burning or ... said. Although abuse by high-profile professional athletes ...
(Date:9/16/2014)... School of Medicine researcher Dr. Jeffrey Samet and ... recently awarded a five year, $5 million grant ... their project titled: Improving Physician Opioid Prescribing for ... are the second most commonly abused substances in ... to prescription opioids now exceed deaths from motor ...
(Date:9/16/2014)... Since the adoption of pediatric legislation, ... in line with increased investment in R&D for pediatric ... novel paediatric information and more than 130 products have ... there has been 221 changes relating to the efficacy ... old or new trials in children and 89 additions ...
(Date:9/16/2014)... testing ground, researchers at Johns Hopkins have shown that ... can substantially reduce patient wait times and possibly improve ... report on the pilot study, published online Sept. 9, ... so-called "Just-in-Time" training and inventory process used now by ... keep complicated operations from bottlenecking. , "We realized that ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 RxAnte, ... predictive analytics and targeted clinical programs, today announced ... changes support the Company’s drive to improve medication ... targeted clinical programs. On September 2, 2014, Brock ... Millennium Health, announced that RxAnte founder and President ...
Breaking Medicine News(10 mins):Health News:1 in 5 U.S. Men Admits to Violence Against Spouse, Partner 2Health News:Paediatric Drug Development Market Analysed by CBR Pharma Insights in In-demand Report Available at MarketPublishers.com 2Health News:Paediatric Drug Development Market Analysed by CBR Pharma Insights in In-demand Report Available at MarketPublishers.com 3Health News:Patients waiting too long to see doctor? Try 'just-in-time' management methods, researchers urge 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 3
... Rao, an American scientist of Indian origin has been ... a new system which makes use of data for ... is the Senior Director of Engineering Research Development at ... ,Rao is reported to have contributed towards ...
... drinkers go in for wholesome and healthy food, beer drinkers ... also seen among// wine drinkers when compared to beer ... in Copenhagen have found that beer drinkers buy unhealthy food ... prefer wine, according to BBC News. ,Studying ...
... Jefferson and colleagues from Cochrane Collaboration (International private organization ... trials) reviewed data from over 50 clinical trials involving ... researchers found that the old drugs which were used ... some drugs like amantadine and rimantidine which were used ...
... employ people with Asperger's Syndrome, who suffer from difficulties ... total of 50,000 people who suffer from this disorder, ... //People who suffer from the Asperger's Syndrome have difficulty ... though the intelligence of those who suffer from this ...
... Researchers from McMaster University has reported in the Journal ... found that the scientists screened 480 strains of Streptomyces ... all the strains were multi-drug resistance //as they were ... antibiotics. ,The researchers were astonished by ...
... transmission case is due today in Harbin court today. The ... blood collected from an infected couple who sold their blood ... Northeast China. // It was found that 15 people were ... and the other four got infection indirectly from the infected, ...
Cached Medicine News:
(Date:9/16/2014)... 2014 Adaptive Biotechnologies, a clinical stage diagnostics ... the adaptive immune system, is pleased to announce the ... Officer (CCO). The addition of Brain to the Company,s ... leading global healthcare companies, including Dean Schorno ... Genomic Health and Sean Nolan (CTO) from ...
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, ... Boston and their first West Coast location in ... Street in Boston , and will house product ... Southern California office will be located at ... the demands of customers nationwide.  Both new locations will be ...
(Date:9/16/2014)... Sept. 16, 2014  Formex, LLC ("Formex"), ... that Mr. Greg Weilersbacher joined Formex as Director ... Greg Weilersbacher has ... focused expertise in Quality Assurance, Facility Validation, ... Weilersbacher brings to Formex a diverse wealth ...
Breaking Medicine Technology:Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
... R.I., Aug. 16, 2011 Medicare Part D beneficiaries ... pay 100 percent of previously subsidized prescription costs, are ... are to switch to more affordable or generic medications, ... concludes. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) The ...
... Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ) ... Phase III clinical studies in patients with refractory chronic ... of the American Medical Association ( JAMA ). ... significant and sustained reductions in uric acid levels along ...
Cached Medicine Technology:CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 2CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 2Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 5Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 6Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 7Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 8
125I radioimmunoassay, Simple extraction procedure, Ready-to-use calibrators, Less than 0.1% crossreactivity with DHEA-SO4, 2-hour single incubation, 37C, Calibration Range: 0.5 30 ng/mL...
Inquire...
EL-RF/3 is for measurement of IgM, IgG, IgA RF with high specificity for rheumatoid arthritis....
Rapid latex slide agglutination assay for the qualitative and semi-quantitative determination of Rheumatoid Factors in human serum....
Medicine Products: